Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8(+) T Cell Responses via CD169(+) Macrophages and cDC1

Successful anti-cancer vaccines aim to prime and reinvigorate cytotoxic T cells and should therefore comprise a potent antigen and adjuvant. Antigen targeting to splenic CD169(+) macrophages was shown to induce robust CD8(+) T cell responses via antigen transfer to cDC1. Interestingly, CD169(+) macr...

Descripción completa

Detalles Bibliográficos
Autores principales: Grabowska, Joanna, Stolk, Dorian A., Nijen Twilhaar, Maarten K., Ambrosini, Martino, Storm, Gert, van der Vliet, Hans J., de Gruijl, Tanja D., van Kooyk, Yvette, den Haan, Joke M.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830461/
https://www.ncbi.nlm.nih.gov/pubmed/33467048
http://dx.doi.org/10.3390/vaccines9010056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830461/
https://www.ncbi.nlm.nih.gov/pubmed/33467048
http://dx.doi.org/10.3390/vaccines9010056

Ejemplares similares